BR0010746A - Derivados heterocìclicos úteis com agentes anticâncer - Google Patents

Derivados heterocìclicos úteis com agentes anticâncer

Info

Publication number
BR0010746A
BR0010746A BR0010746-8A BR0010746A BR0010746A BR 0010746 A BR0010746 A BR 0010746A BR 0010746 A BR0010746 A BR 0010746A BR 0010746 A BR0010746 A BR 0010746A
Authority
BR
Brazil
Prior art keywords
anticancer agents
heterocyclic derivatives
derivatives useful
above compounds
compounds
Prior art date
Application number
BR0010746-8A
Other languages
English (en)
Inventor
Thomat George Gant
Mark Carl Noe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0010746A publication Critical patent/BR0010746A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Patente de Invenção: "DERIVADOS HETEROCìCLICOS úTEIS COM AGENTES ANTICâNCER". A invenção presente refere-se a compostos com a fórmula 1: e aos seus sais, precursores e solvatos farmaceuticamente aceitáveis, em que Z, X, X^ 1^, R^ 1^, R^ 2^ e R^ 3^ são tal como aqui definidos bem como a composições farmacêuticas que contêm os compostos anteriores para o tratamento de distúrbios mediados pela angiogênese em mamíferos pela administração dos compostos anteriores.
BR0010746-8A 1999-05-19 2000-05-03 Derivados heterocìclicos úteis com agentes anticâncer BR0010746A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13493399P 1999-05-19 1999-05-19
PCT/IB2000/000570 WO2000071532A1 (en) 1999-05-19 2000-05-03 Heterocyclic derivatives useful as anticancer agents

Publications (1)

Publication Number Publication Date
BR0010746A true BR0010746A (pt) 2002-02-13

Family

ID=22465672

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010746-8A BR0010746A (pt) 1999-05-19 2000-05-03 Derivados heterocìclicos úteis com agentes anticâncer

Country Status (21)

Country Link
US (1) US6380214B1 (pt)
EP (1) EP1187826B1 (pt)
JP (2) JP3692041B2 (pt)
AR (1) AR029634A1 (pt)
AT (1) ATE349440T1 (pt)
AU (1) AU4137400A (pt)
BR (1) BR0010746A (pt)
CA (1) CA2374247C (pt)
CO (1) CO5170417A1 (pt)
DE (1) DE60032601T2 (pt)
DZ (1) DZ3042A1 (pt)
ES (1) ES2276681T3 (pt)
GT (1) GT200000069A (pt)
HN (1) HN2000000051A (pt)
MA (1) MA26733A1 (pt)
MX (1) MXPA01011920A (pt)
PA (1) PA8494101A1 (pt)
PE (1) PE20010152A1 (pt)
TN (1) TNSN00104A1 (pt)
UY (1) UY26143A1 (pt)
WO (1) WO2000071532A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
JP2003522174A (ja) 2000-02-07 2003-07-22 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存性キナーゼの３−アミノピラゾール阻害剤
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
PT1401825E (pt) * 2001-06-11 2009-10-23 Virochem Pharma Inc Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US6989451B2 (en) * 2002-06-04 2006-01-24 Valeant Research & Development Heterocyclic compounds and uses thereof
CA2489355A1 (en) * 2002-06-13 2003-12-24 Qlt Inc. Methods of using isothiazole derivatives to treat cancer or inflammation
US7649012B2 (en) * 2002-07-09 2010-01-19 Fasgen, Inc. Compounds, pharmaceutical compositions containing same, and methods of use for same
SG149701A1 (en) * 2002-07-09 2009-02-27 Fasgen Llc Methods of treating microbial infections in humans and animals
JP4511352B2 (ja) * 2002-07-25 2010-07-28 ファイザー・インク 抗癌薬として有用なイソチアゾール誘導体
WO2004050681A2 (en) * 2002-11-15 2004-06-17 Exelixis, Inc. Kinase modulators
ES2345438T3 (es) * 2002-12-10 2010-09-23 Virochem Pharma Inc. Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus.
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
ES2527185T3 (es) * 2003-03-07 2015-01-21 Santen Pharmaceutical Co., Ltd Nuevos compuestos que tienen un grupo 4-piridilalquiltio como sustituyente
CA2526636C (en) 2003-05-20 2012-10-02 Bayer Pharmaceuticals Corporation Diaryl ureas for diseases mediated by pdgfr
CL2004001834A1 (es) 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
CN1918127B (zh) * 2004-02-17 2012-02-15 参天制药株式会社 具有引入了取代或无取代氨基的4-吡啶基烷硫基的环状化合物
JP4626353B2 (ja) * 2004-02-17 2011-02-09 参天製薬株式会社 置換又は無置換アミノ基を導入した４−ピリジルアルキルチオ基を有する新規環式化合物
DK1717229T3 (da) * 2004-02-17 2011-09-19 Santen Pharmaceutical Co Ltd Ny cyklisk forbindelse med 4-pyridylalkylthiogruppe med deri indført (u)substitueret amino
EP1735284A1 (en) 2004-03-18 2006-12-27 Pfizer Limited N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
MXPA06012394A (es) 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
KR100893977B1 (ko) * 2004-08-26 2009-04-20 화이자 프로덕츠 인코포레이티드 이소티아졸 유도체의 제조 방법
JP4585978B2 (ja) * 2005-03-03 2010-11-24 参天製薬株式会社 キノリルアルキルチオ基を有する新規環式化合物
JP5030947B2 (ja) 2005-05-13 2012-09-19 ヴァイロケム・ファーマ・インコーポレーテッド フラビウイルス感染の治療及び予防のための化合物及び方法
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
KR20090086081A (ko) * 2006-11-15 2009-08-10 바이로켐 파마 인코포레이티드 플라비바이러스 감염의 치료 또는 예방용 티오펜 유사체
US7977371B2 (en) 2007-02-26 2011-07-12 Santen Pharmaceutical Co., Ltd. Pyrrole derivative having ureido group and aminocarbonyl group as substituents
TW200911240A (en) * 2007-06-11 2009-03-16 Kyowa Hakko Kogyo Kk Anti-tumor agent
MX2010001636A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
WO2010151710A2 (en) * 2009-06-25 2010-12-29 Medolution Limited Substituted heterocyclic compounds as kinases inhibitors and method of use thereof
RU2014141674A (ru) 2012-03-16 2016-05-10 Аксикин Фармасьютикалз, Инк. 3,5-диаминопиразоловые ингибиторы киназы
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
UA118312C2 (uk) 2014-12-23 2018-12-26 Ексікін Фармасутікалз, Інк. 3,5-діамінопіразолові інгібітори кінази

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1950990A1 (de) * 1968-10-17 1970-05-14 Ciba Geigy Verfahren zur Herstellung von neuen triazacyclischen Verbindungen
GB1355513A (en) * 1971-04-07 1974-06-05 May & Baker Ltd Isothiazole derivatives
DE2408234A1 (de) * 1974-02-21 1975-09-04 Celamerck Gmbh & Co Kg Isothiazolylharnstoffe
US4057416A (en) * 1976-06-18 1977-11-08 Fmc Corporation 3-Alkylthio-, 3-alkylsulfinyl-, and 3-alkylsulfonylisothiazole derivatives as herbicides
US4075001A (en) * 1976-06-18 1978-02-21 Fmc Corporation 3-Aminoisothiazole derivatives as herbicides
US4059433A (en) * 1976-06-18 1977-11-22 Fmc Corporation 3-Alkoxyisothiazole derivatives as herbicides
DE3529247A1 (de) * 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung
DE3540377A1 (de) * 1985-11-14 1987-05-21 Bayer Ag Thienooxazinone, verfahren zu ihrer herstellung und ihre verwendung als leistungsfoerderer
DE3541631A1 (de) * 1985-11-26 1987-05-27 Bayer Ag Selektiv-fungizide verwendung von thienylharnstoff-derivaten
US4859699A (en) * 1987-07-20 1989-08-22 Sandoz Ltd. Substituted N-benzoyl-N'-thienylureas
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
DE4328425A1 (de) * 1993-08-24 1995-03-02 Basf Ag Acylamino-substituierte Isoxazol- bzw. Isothiazolderivate, Verfahren zu deren Herstellung und ihre Verwendung
TW276256B (pt) * 1993-08-26 1996-05-21 Takeda Pharm Industry Co Ltd
WO1996014843A2 (en) * 1994-11-10 1996-05-23 Cor Therapeutics, Inc. Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
US5792767A (en) * 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
EP0986382B1 (en) * 1997-05-23 2008-06-25 Bayer Pharmaceuticals Corporation Raf kinase inhibitors
US6037340A (en) * 1997-05-28 2000-03-14 Cadus Pharmaceutical Corporation Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця

Also Published As

Publication number Publication date
TNSN00104A1 (fr) 2005-11-10
AR029634A1 (es) 2003-07-10
EP1187826B1 (en) 2006-12-27
MXPA01011920A (es) 2002-05-06
MA26733A1 (fr) 2004-12-20
WO2000071532A1 (en) 2000-11-30
AU4137400A (en) 2000-12-12
JP2005008641A (ja) 2005-01-13
ES2276681T3 (es) 2007-07-01
ATE349440T1 (de) 2007-01-15
DZ3042A1 (fr) 2004-03-27
CA2374247A1 (en) 2000-11-30
PA8494101A1 (es) 2003-09-05
DE60032601T2 (de) 2007-11-15
CA2374247C (en) 2008-01-22
JP3692041B2 (ja) 2005-09-07
US6380214B1 (en) 2002-04-30
JP2003500401A (ja) 2003-01-07
GT200000069A (es) 2001-11-08
CO5170417A1 (es) 2002-06-27
PE20010152A1 (es) 2001-02-08
UY26143A1 (es) 2000-12-29
HN2000000051A (es) 2001-02-02
EP1187826A1 (en) 2002-03-20
DE60032601D1 (de) 2007-02-08

Similar Documents

Publication Publication Date Title
BR0010746A (pt) Derivados heterocìclicos úteis com agentes anticâncer
BRPI9913138B8 (pt) derivado de quinolin-2-ona substituído com alquinila e composição farmacêutica contendo o mesmo
BR9906013A (pt) Derivados bicìclicos heteroaromáticos úteis como agentes anticancerìgenos
BRPI0313942B8 (pt) derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas
BR9910900A (pt) Derivados isotiazol úteis como agentes anticancerìgenos
MXPA03005464A (es) Agentes antivirales.
BR9814018A (pt) Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer
BR9916980A (pt) Derivados bicìclicos substituìdos úteis como agentes anticancerìgenos
BR9713552A (pt) Derivados de pirimidina bicìclicos condensados
BR0015911A (pt) Derivados de benzoimidazole úteis como agentes antiproliferativos
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
BR0014178A (pt) Derivados de ácido dicarboxìlico com propriedades farmacêuticas
UY25679A1 (es) Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
BR0111548A (pt) Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal
SE9904508D0 (sv) New compounds
BR0010938A (pt) Derivados da 13-metil eritromicina
DK1697370T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
BRPI0412899A (pt) composto para inibir a atividade de parp, usos de uma quantidade terapêutica e uma quantidade terapeuticamente efetiva de um composto e de seus sais farmaceuticamente aceitáveis, uso de um composto, composição farmacêutica, e, método para o tratamento de cáncer em mamìferos
BR0111377A (pt) Derivados de tiofeno úteis como agentes anticancerìgenos
BR9810021A (pt) Derivados 9-oxima-eritromicina
NO20021367D0 (no) Indolyl-3-glyoksylsyrederivater som har terapeutisk verdifulle egenskaper
BRPI0409465A (pt) derivados de carboxamida como agentes antidiabéticos
BR9905089A (pt) Derivados macrolìdeos
BR0312798A (pt) Derivados de isotiazol úteis como agentes anticancerìgenos
BR0006299A (pt) Derivados da 4-oxo-2-ureìdo-1,4,5,6-tetra-hidro-pirimidina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10(VIII), 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.